AG-ATOMOXETINE CAPSULE

देश: कनाडा

भाषा: अंग्रेज़ी

स्रोत: Health Canada

इसे खरीदें

सक्रिय संघटक:

ATOMOXETINE (ATOMOXETINE HYDROCHLORIDE)

थमां उपलब्ध:

ANGITA PHARMA INC.

ए.टी.सी कोड:

N06BA09

INN (इंटरनेशनल नाम):

ATOMOXETINE

डोज़:

25MG

फार्मास्यूटिकल फॉर्म:

CAPSULE

रचना:

ATOMOXETINE (ATOMOXETINE HYDROCHLORIDE) 25MG

प्रशासन का मार्ग:

ORAL

पैकेज में यूनिट:

100

प्रिस्क्रिप्शन प्रकार:

Prescription

चिकित्सीय क्षेत्र:

MISCELLANEOUS CENTRAL NERVOUS SYSTEM AGENTS

उत्पाद समीक्षा:

Active ingredient group (AIG) number: 0150434003; AHFS:

प्राधिकरण का दर्जा:

APPROVED

प्राधिकरण की तारीख:

2020-11-30

उत्पाद विशेषताएं

                                AG-ATOMOXETINE Product Monograph
Page 1
PRODUCT MONOGRAPH
PR
AG-ATOMOXETINE
Atomoxetine Capsules
10, 18, 25, 40, 60, 80 and 100 mg atomoxetine (as atomoxetine
hydrochloride)
House standard
SELECTIVE NOREPINEPHRINE REUPTAKE INHIBITOR
FOR ATTENTION-DEFICIT/HYPERACTIVITY DISORDER (ADHD)
Angita Pharma Inc.
1310, rue Nobel
Boucherville, Québec
J4B 5H3
Date of Revision:
November 26, 2020
Submission Control No. 245703
AG-ATOMOXETINE Product Monograph
Page 2
TABLE OF CONTENTS
PART I: HEALTH PROFESSIONAL INFORMATION
..................................................... 3
SUMMARY PRODUCT INFORMATION
.......................................................................
3
INDICATIONS AND CLINICAL USE
..........................................................................
3
CONTRAINDICATIONS
...................................................................................................
4
WARNINGS AND PRECAUTIONS
.................................................................................
5
ADVERSE REACTIONS
.................................................................................................
12
DRUG ABUSE AND DEPENDENCE
............................................................................
22
DRUG INTERACTIONS
..................................................................................................
23
DOSAGE AND ADMINISTRATION
.............................................................................
24
OVERDOSAGE
.................................................................................................................
27
ACTION AND CLINICAL PHARMACOLOGY
........................................................... 28
STORAGE AND STABILITY
.........................................................................................
32
DOSAGE FORMS, COMPOSITION AND PACKAGING
........................................... 33
PART II: SCIENTIFIC INFORMATION
............................................................................
34
PHARMACEUTICAL INFORMATION
........................
                                
                                पूरा दस्तावेज़ पढ़ें
                                
                            

अन्य भाषाओं में दस्तावेज़

उत्पाद विशेषताएं उत्पाद विशेषताएं फ़्रेंच 26-11-2020

इस उत्पाद से संबंधित अलर्ट देखें

दस्तावेज़ इतिहास देखें